BioCentury | May 13, 2013
Clinical News

Cycloset bromocriptine mesylate regulatory update

...Santarus Inc. (NASDAQ:SNTS, San Diego, Calif.) and VeroScience announced that Cycloset bromocriptine was included in the...
...by the American Association of Clinical Endocrinologists (AACE). The algorithm recommended dual therapy to include Cycloset...
...actively promoting Cycloset (see BioCentury, Sept. 13, 2010). VeroScience LLC , Tiverton, R.I. Product: Cycloset bromocriptine mesylate...
BioCentury | Nov 22, 2010
Company News

Santarus, S2 Therapeutics Inc., VeroScience sales and marketing update

...Santarus launched Cycloset bromocriptine in the U.S. to treat Type II diabetes. VeroScience and S2 granted...
...right to co-promote Cycloset in portions of the U.S., where Santarus is not actively promoting Cycloset...
BioCentury | Sep 13, 2010
Finance

Regulatory milestones

...rights from partners VeroScience LLC and S2 Therapeutics Inc. to commercialize Type II diabetes drug Cycloset...
BioCentury | Sep 13, 2010
Company News

S2 Therapeutics Inc., Santarus, VeroScience sales and marketing update

...and S2 granted Santarus exclusive rights in the U.S. to commercialize Type II diabetes drug Cycloset...
...right to co-promote Cycloset in portions of the U.S., where Santarus is not actively promoting Cycloset...
BioCentury | Sep 9, 2010
Company News

Santarus to market Cycloset in the U.S.

...granted Santarus Inc. (NASDAQ:SNTS) exclusive rights in the U.S. to commercialize Type II diabetes drug Cycloset...
...right to co-promote Cycloset in portions of the U.S. where Santarus is not actively promoting Cycloset...
BioCentury | May 18, 2009
Product Development

Now the hard part

...It has been a long slog to approval for Cycloset bromocriptine, and the hard part is...
...drug with moderate efficacy and a common side effect of nausea, but proven cardiovascular safety. Cycloset...
...three-year head start by the time Cycloset reaches the market. According to the drugs' labels, Cycloset...
BioCentury | May 11, 2009
Clinical News

Cycloset regulatory update

...FDA approved an NDA from VeroScience for Cycloset bromocriptine timed-release tablets to treat Type II diabetes...
...to sublicense worldwide marketing rights to a third party. VeroScience LLC , Tiverton, R.I. Product: Cycloset...
BioCentury | May 7, 2009
Company News

VeroScience's Cycloset approved for diabetes

...FDA approved an NDA from VeroScience LLC (Tiverton, R.I.) for Cycloset bromocriptine timed-release tablets to treat...
BioCentury | Dec 15, 2008
Regulation

Diabetes clock-watching

...Lilly (NYSE:LLY) Alogliptin/Actos pioglitazone Oral combination of alogliptin plus pioglitazone sNDA submitted in September VeroScience Cycloset...
BioCentury | Dec 15, 2008
Regulation

Diabetes safety test

...six Phase III trials in 4,000 patients treated with the DPP-4 inhibitor. An NDA for Cycloset...
Items per page:
1 - 10 of 66